GET DAILY SIGNALSExagen (XGN) Shares Drop -52% in 30 Days: Analyzing the Recent Selloff
Key Takeaways
- Exagen shares have dropped roughly 52% over the past 30 days, falling from about $8.42 on October 14, 2026, to around $4.05 intraday on November 13, 2026.
- The decline accelerated after third-quarter 2026 results, which showed a wider-than-expected loss and a sharp slowdown in AVISE CTD test-volume growth.
- A newly filed $50 million at-the-market offering, part of a $150 million shelf registration, added dilution concerns for shareholders.
- Several analysts lowered their price targets to $9 from $11 while keeping Buy ratings on the stock.
- Management reiterated full-year 2026 revenue guidance of $72 million to $75 million and highlighted its myositis test pipeline targeting a 2027 launch.
- For additional detail on this ticker's Price Targets, Earnings, and Forecast, visit the dedicated Tickeron pages.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Exagen (XGN) Company Overview and Market Position
Exagen Inc. (XGN) is a precision-medicine diagnostics company headquartered in Carlsbad, California, focused on bringing clarity to autoimmune disease testing. Its flagship product is the AVISE CTD test, a proprietary blood test that helps clinicians diagnose and monitor connective tissue diseases, including systemic lupus erythematosus (lupus). The company also operates a growing pharma services business that supports biopharmaceutical partners.
Exagen generates revenue primarily on a per-test basis, with a trailing twelve-month average selling price of approximately $451, its fourteenth consecutive quarterly improvement. Management estimates the company holds roughly 3% to 4% of an autoimmune testing market it values at more than $2 billion. Investors follow the stock for its pricing power, its myositis test pipeline, and its progress toward profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Exagen (XGN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Exagen shares have fallen about 52%, declining from a closing price of $8.42 on October 14, 2026, to around $4.05 intraday on November 13, 2026. The move was punctuated by a roughly 26% single-session decline following the third-quarter earnings report on November 10, followed by continued selling pressure over subsequent sessions.
The broader quarterly picture is more volatile. From a mid-August level of about $6.58, the stock rallied to an intraday peak near $9.21 in mid-October before reversing sharply. Measured over the trailing three months, shares are down roughly 38%, reflecting both the strong first-half momentum that lifted the stock and the steep pullback that followed the latest results.
What Drove XGN Stock Price in the Last 30 Days
The primary catalyst was Exagen's third-quarter 2026 earnings report released on November 10. The company posted revenue of $18.42 million, up 7% year over year and slightly above the consensus estimate of about $18.34 million. However, GAAP net loss per share came in at $0.25, missing the roughly $0.18 loss analysts expected. More importantly for investors, AVISE CTD test-volume growth slowed to about 2% year over year, down sharply from 11% in the prior quarter, raising questions about the durability of near-term growth.
Dilution concerns compounded the selloff. Shortly after reporting results, Exagen filed a registration statement covering up to $150 million in securities, including a $50 million at-the-market offering with TD Cowen. Analysts responded by lowering price targets: Canaccord Genuity and Roth Capital each cut their targets to $9 from $11 while maintaining Buy ratings, and BTIG reiterated a $9 target.
What Drove XGN Stock Performance Over the Last Quarter
Exagen's quarterly trajectory was shaped by two opposing forces. Strong second-quarter 2026 results and raised full-year guidance helped drive the stock higher through late September, supported by improving average selling prices and enthusiasm around the myositis pipeline. Trailing twelve-month average selling price reached a record $451, and pharma services revenue grew about 85% year to date.
That momentum reversed after the third-quarter report revealed decelerating volume growth and higher operating expenses. A widening operating loss, elevated stock-based compensation, and the new share-sale program shifted investor sentiment, and the stock gave back most of its earlier gains.
XGN Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor whether AVISE CTD volume growth reaccelerates in the fourth quarter and whether management delivers on its reiterated full-year revenue guidance of $72 million to $75 million. The company's December 15, 2026 investor webcast on the myositis test and broader pipeline is a key near-term event, as is the planned New York State submission expected by the end of January 2027 ahead of an early-2027 launch.
Other factors to watch include the pace of any share sales under the at-the-market program, pharma services backlog growth, and potential reimbursement changes from PAMA that could pressure pricing in 2027. Progress toward adjusted EBITDA breakeven and continued average-selling-price growth will also shape sentiment. From what I see, this is important because it ties directly into the company's path to profitability.
Using Tickeron AI Tools in My Research
I often turn to Tickeron’s Trending AI Robots when evaluating how different automated strategies are positioned around a name like this one. The section highlights top-performing bots across various timeframes and approaches, which helps me compare signals without relying on just one source. It’s a practical way to see real-time algorithmic responses to events like the recent earnings miss and dilution news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
XGN's RSI Oscillator entering oversold zone
The RSI Indicator for XGN moved into overbought territory on November 12, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in 190 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XGN as a result. In 76 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for XGN turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 30 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
XGN moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XGN crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for XGN entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.522) is normal, around the industry mean (67.298). P/E Ratio (-7.085) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.592) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases
Industry MedicalSpecialties
Advertisement